Targacept Inc (TRGT)

0.63
0.05 8.01
NASDAQ : Health Care
Prev Close 0.68
Open 0.68
Day Low/High 0.62 / 0.70
52 Wk Low/High 1.16 / 21.60
Volume 95.64K
Avg Volume 68.90K
Exchange NASDAQ
Shares Outstanding 34.29M
Market Cap 75.79M
EPS -0.97
P/E Ratio 3.84
Div & Yield N.A. (N.A)

Latest News

Targacept And Catalyst Biosciences Amend Definitive Merger Agreement

Targacept And Catalyst Biosciences Amend Definitive Merger Agreement

Targacept, Inc. (NASDAQ: TRGT) and Catalyst Biosciences, Inc.

3 Stocks Under $10 to Trade for Big Breakouts

3 Stocks Under $10 to Trade for Big Breakouts

These under-$10 stocks are within range of triggering breakout trades.

Targacept Announces Negative Top-Line Results From Exploratory Study Of TC-6499 In Diabetic Gastroparesis

Targacept Announces Negative Top-Line Results From Exploratory Study Of TC-6499 In Diabetic Gastroparesis

Targacept, Inc. (NASDAQ: TRGT) today announced top-line results from a Phase 1/2 exploratory study of TC-6499 as a treatment for diabetic gastroparesis, a chronic disorder that slows or stops the passage of food from the...

Targacept Reports Third Quarter 2014 Financial Results

Targacept Reports Third Quarter 2014 Financial Results

Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company advancing NNR Therapeutics™, today reported its financial results for the third quarter and nine months ended September 30, 2014.

Targacept To Report Third Quarter 2014 Financial Results On November 5, 2014

Targacept To Report Third Quarter 2014 Financial Results On November 5, 2014

Targacept Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company advancing NNR Therapeutics™, today announced that it will report financial results for the third quarter of 2014 on Wednesday, November 5,...

Targacept Reports Second Quarter 2014 Financial Results

Targacept Reports Second Quarter 2014 Financial Results

Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company advancing NNR Therapeutics™, today reported its financial results for the second quarter and six months ended June 30, 2014.

Targacept To Report Second Quarter 2014 Financial Results On August 6, 2014

Targacept To Report Second Quarter 2014 Financial Results On August 6, 2014

Targacept Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company advancing NNR Therapeutics™, today announced it will report financial results for the second quarter of 2014 on Wednesday, August 6, 2014,...

Targacept To Discontinue TC-5214 Overactive Bladder Program

Targacept To Discontinue TC-5214 Overactive Bladder Program

Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company advancing NNR Therapeutics™, today announced top-line results from a Phase 2b clinical trial of TC-5214 as a treatment for overactive ...

Targacept Phase 2b Clinical Trial In Alzheimer’s Disease Does Not Show Superiority Of TC-1734 Over Donepezil

Targacept Phase 2b Clinical Trial In Alzheimer’s Disease Does Not Show Superiority Of TC-1734 Over Donepezil

Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today announced top-line results from a Phase 2b monotherapy clinical trial of TC-1734 as a treatment...

Targacept Initiates Exploratory Study Of TC-6499 In Diabetic Gastroparesis

Targacept Initiates Exploratory Study Of TC-6499 In Diabetic Gastroparesis

Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today announced the initiation of a Phase 1/2 exploratory study of TC-6499 as a treatment for...

Targacept Reports First Quarter 2014 Financial Results

Targacept Reports First Quarter 2014 Financial Results

Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today reported its financial results for the first quarter ended March 31, 2014.

Targacept Announces Participation In Upcoming Conferences

Targacept Announces Participation In Upcoming Conferences

Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today announced that Dr.

Targacept To Report First Quarter 2014 Financial Results On May 7, 2014

Targacept To Report First Quarter 2014 Financial Results On May 7, 2014

Targacept Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today announced that it will report financial results for the first quarter of 2014 on the morning of ...

Targacept To Present At The 13th Annual Needham Healthcare Conference

Targacept To Present At The 13th Annual Needham Healthcare Conference

Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today announced that Dr.

Targacept To Present At The Cowen And Company 34th Annual Health Care Conference

Targacept To Present At The Cowen And Company 34th Annual Health Care Conference

Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today announced that Dr.

Targacept Reports Fourth Quarter And 2013 Financial Results

Targacept Reports Fourth Quarter And 2013 Financial Results

Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today reported its financial results for the fourth quarter and year ended December 31, 2013.

Targacept Completes Recruitment In Phase 2b Overactive Bladder Trial Of TC-5214

Targacept Completes Recruitment In Phase 2b Overactive Bladder Trial Of TC-5214

Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today announced that it has completed recruitment of patients in its Phase 2b clinical study of...

5 Stocks Poised for Breakouts

5 Stocks Poised for Breakouts

These stocks are ready to break out and trade higher from current levels.

Targacept To Report Fourth Quarter And 2013 Financial Results On February 13, 2014

Targacept To Report Fourth Quarter And 2013 Financial Results On February 13, 2014

Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today announced it will report financial results for the fourth quarter and year ended December 31,...

Targacept To Present At The 16th Annual BIO CEO & Investor Conference

Targacept To Present At The 16th Annual BIO CEO & Investor Conference

Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today announced that Dr.

Short Interest Drops 26% For TRGT

Short Interest Drops 26% For TRGT

The most recent short interest data has been released by the NASDAQ for the 12/31/2013 settlement date, which shows a 476,428 share decrease in total short interest for Targacept Inc , to 1,366,754, a decrease of 25.85% since 12/13/2013. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Targacept Appoints John P. Richard As Chairman Of The Board Of Directors

Targacept Appoints John P. Richard As Chairman Of The Board Of Directors

Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today announced that John P.

Interesting TRGT Put And Call Options For August 16th

Interesting TRGT Put And Call Options For August 16th

Investors in Targacept Inc saw new options become available this week, for the August 16th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 225 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Commit To Buy Targacept Inc At $2.50, Earn 12.8% Annualized Using Options

Commit To Buy Targacept Inc At $2.50, Earn 12.8% Annualized Using Options

Investors eyeing a purchase of Targacept Inc stock, but tentative about paying the going market price of $4.11/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the August 2014 put at the $2.50 strike, which has a bid at the time of this writing of 20 cents.

Targacept Announces Negative Top-Line Results From Phase 2b Clinical Trial Of TC-5619 In Schizophrenia

Targacept Announces Negative Top-Line Results From Phase 2b Clinical Trial Of TC-5619 In Schizophrenia

Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics ™, today announced top-line results from a Phase 2b clinical trial of TC-5619 as an augmentation ...

Targacept Announces Presentations At Upcoming Conferences

Targacept Announces Presentations At Upcoming Conferences

Targacept, Inc. (NASDAQ:TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today announced that Dr.

Targacept Reports Third Quarter 2013 Financial Results

Targacept Reports Third Quarter 2013 Financial Results

Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today reported its financial results for the third quarter and nine months ended September 30, 2013.